Key result
In patients with acute myocardial infarction, Cilotax stents were associated with higher pre-matching rates of major adverse cardiovascular events compared to everolimus-eluting stents.
Why the study?
The study was conducted to compare the safety and effectiveness of paclitaxel/cilostazol-eluting Cilotax stents with everolimus-eluting stents in patients with acute myocardial infarction.
Does the paclitaxel/cilostazol-eluting Cilotax stent reduce target lesion failure compared to everolimus-eluting stents in patients with acute myocardial infarction?
Observational (n=5,472)
Does the paclitaxel/cilostazol-eluting Cilotax stent reduce target lesion failure compared to everolimus-eluting stents in patients with acute myocardial infarction?
The use of paclitaxel/cilostazol-eluting Cilotax stents in acute myocardial infarction is associated with higher rates of adverse events, including stent thrombosis, compared to everolimus-eluting stents and should be avoided.
Answers are grounded in this paper and cite their sources.
Cilotax stents were associated with higher TLR and ST rates than EES in AMI PCI; observational data leave open causal inference and practice change.
BACKGROUND: This study compared the safety and effectiveness of paclitaxel/cilostazol-eluting Cilotax stents with those of everolimus-eluting stents in patients with acute myocardial infarction. Real-world data from the Korea Acute Myocardial Infarction Registry were examined. METHODS: A total of 5,472 patients with acute myocardial infarction underwent percutaneous coronary intervention with Cilotax stents (n = 212) or everolimus-eluting stents (n = 5,260). The primary end point was the 3-year rate of target lesion failure. The other end points were major adverse cardiovascular events (a composite of cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization), target vessel revascularization, and stent thrombosis. A propensity score matching analysis was performed to adjust for potential confounders by using a logistic regression model; propensity score matching generated 2 well-balanced groups (Cilotax group, n = 180; everolimus-eluting stents group, n = 170; N = 350). After propensity score matching, baseline clinical characteristics were similar between the groups. RESULTS: After percutaneous coronary intervention, compared with the everolimus-eluting stents group, the Cilotax group more often had major adverse cardiovascular events (24.1% vs 18.5%; P = .042), myocardial infarction (8.0% vs 3.2%; P < .001), target lesion revascularization (8.0% vs 2.6%; P < .001), target vessel revascularization (11.3% vs 4.5%; P < .001), and stent thrombosis (4.7% vs 0.5%; P < .001) before matching. Even after matching, the Cilotax group had more frequent target lesion revascularization (9.4% vs 2.9%; P = .22) and stent thrombosis (5.6% vs 1.2%; P = .34). CONCLUSION: In patients with acute myocardial infarction who underwent percutaneous coronary intervention, use of the Cilotax stent was associated with higher rates of target lesion revascularization, target vessel revascularization, and stent thrombosis than were everolimus-eluting stents. Use of the Cilotax dual drugeluting stent should be avoided in the treatment of myocardial infarction.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2024) conducted an observational in Acute myocardial infarction (n=5,472). Cilotax dual drug-eluting stent vs. Everolimus-eluting stents was evaluated on 3-year rate of target lesion failure. In patients with acute myocardial infarction, Cilotax stents were associated with higher pre-matching rates of major adverse cardiovascular events compared to everolimus-eluting stents.
Synapse has enriched 10 related papers. Consider them for comparative context: